Arcus Biosciences Inc (RCUS)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 150,000 | 127,000 | 206,000 | 148,000 | 173,415 |
| Short-term investments | US$ in thousands | 828,000 | 632,000 | 803,000 | 351,394 | 555,231 |
| Total current liabilities | US$ in thousands | 226,000 | 184,000 | 193,000 | 166,000 | 121,669 |
| Cash ratio | 4.33 | 4.12 | 5.23 | 3.01 | 5.99 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($150,000K
+ $828,000K)
÷ $226,000K
= 4.33
The cash ratio of Arcus Biosciences Inc has shown some fluctuations over the years. As of December 31, 2020, the cash ratio was 5.99, indicating that the company had a high level of cash and cash equivalents relative to its current liabilities. However, by December 31, 2021, the cash ratio decreased to 3.01, suggesting a decrease in the company's ability to cover its short-term obligations with its available cash.
Subsequently, the cash ratio increased to 5.23 by December 31, 2022, indicating that the company had improved its liquidity position compared to the previous year. However, there was a slight decline in the cash ratio to 4.12 by December 31, 2023, which may indicate a potential decrease in the company's ability to meet its short-term financial obligations solely with its cash on hand.
As of December 31, 2024, the cash ratio stood at 4.33, reflecting a slight improvement compared to the previous year but still below the levels seen in 2020 and 2022. Overall, while there have been fluctuations in Arcus Biosciences Inc's cash ratio over the years, the company has generally maintained a decent level of liquidity, although there may be a need to monitor its cash position closely to ensure adequate coverage of its short-term liabilities.
Peer comparison
Dec 31, 2024